The ongoing Ebola outbreak in Congo has led to over a thousand deaths. Efforts being made to contain the outbreak and treat the already affected include various clinical trials on different treatments. Out of four Ebola treatments, two of them emerged to be effective at treating infected patients.
Ebola Treatment Clinical Trials
The four treatments that were compared in the clinical trial are mAb114, REGN-EB3, remdesivir, and ZMapp. These were tested out on 499 patients who were already infected. Each of them was treated with one of the four experimental treatments, which were assigned randomly.
The Ebola outbreak began in Congo in August 2018. So far, as many as 1,888 people have been claimed by the deadly virus. The trial was commenced in November last year. The findings were evaluated on August 9, 2019 and are still awaiting finalization.
The researchers found that two of the treatments had higher success rates than the other two. These were mAb114 or REGN-EB3, which are both antibody treatments. The results show that these treatments increased an Ebola patient’s chances of survival by a significant percentage. The death rate for patients on the REGN-EB3 treatment was 29 percent and 34 percent for mAb114. Patients in the early stage of the virus, with lower viral load had even lower death rates. The therapies have potential to reduce the current 67 percent mortality rate from the ongoing outbreak. The other two, ZMapp, another antibody treatment and the antiviral drug remdesivir, did not work as well.
The next step of the clinical trial is to focus on the two most effective treatments. Medical researchers are going to focus more on getting information on the safety of the drugs as well as the immune responses that patients experience while on the treatment. The size of participants in the tests is not large enough to properly evaluate which of the two treatments is the more effective.